Change in skeletal muscle mass during systemic cancer treatment: a systematic review and meta-analysis
DOI:
https://doi.org/10.2340/1651-226X.2026.45726Keywords:
Sarcopenia, skeletal muscle mass, Cancer, Meta-analysisAbstract
Background and purpose: Loss of skeletal muscle mass (SMM) is common during systemic cancer treatment, but the magnitude and variability across cancer and treatment types remain uncertain. We aimed to describe changes in SMM during systemic cancer treatment supported by pooled quantitative estimates.
Patients/material and methods: We systematically searched PubMed, Embase, and Web of Science until April 2025 for longitudinal studies reporting SMM during chemotherapy and/or immunotherapy (± targeted therapy) in patients with cancer (PROSPERO CRD42022308388). Standardized mean changes (SMC) were pooled in random-effects meta-analyses using the restricted maximum-likelihood estimator with Hartung–Knapp adjustment. Heterogeneity was assessed using I². Risk of bias was assessed with the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.
Results: Seventy-eight studies (n = 10,502; 52% male; median age 64 years [interquartile range, IQR: 34–77]) were included. Meta-analysis across cancers showed an association between systemic cancer treatment and decline in SMM (59 studies; n = 6,373; SMC = −0.24, 95% confidence interval [CI]: −0.29 to −0.20; I² = 92%), corresponding to −5% over a median interval of 90 (IQR: 71–129) days among studies (62%) reporting assessment intervals. Declines were most pronounced during chemotherapy (± targeted therapy).
Interpretation: Declines in SMM are frequently observed during systemic cancer treatment, particularly during chemotherapy (± targeted therapy), although effect sizes were generally small per Cohen’s thresholds. However, substantial heterogeneity limits interpretation of a single pooled estimate. Prospective studies with standardized methods are needed to clarify trajectories, mechanisms and clinical implications of SMM loss.
Downloads
References
Williams GR, Dunne RF, Giri S, Shachar SS, Caan BJ. Sarcopenia in the older adult with cancer. J Clin Oncol. 2021;39(19):2068–78. DOI: https://doi.org/10.1200/JCO.21.00102
Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol. 2018 Feb 1;29(suppl_2):ii1-ii9. 10.1093/annonc/mdx810 DOI: https://doi.org/10.1093/annonc/mdx810
Lavalle S, Valerio MR, Masiello E, Gebbia V, Scandurra G. Unveiling the intricate dance: how cancer orchestrates muscle wasting and sarcopenia. In Vivo. 2024;38(4):1520–9. DOI: https://doi.org/10.21873/invivo.13602
Bland KA, Kouw IWK, van Loon LJC, Zopf EM, Fairman CM. Exercise-based interventions to counteract skeletal muscle mass loss in people with cancer: can we overcome the odds? Sports Med. 2022;52(5):1009–27. DOI: https://doi.org/10.1007/s40279-021-01638-z
Surov A, Wienke A. Prevalence of sarcopenia in patients with solid tumors: a meta-analysis based on 81,814 patients. J Parenter Enteral Nutr. 2022;46(8):1761–8. DOI: https://doi.org/10.1002/jpen.2415
Sullivan ES, Daly L, Power D, Ryan A. Epidemiology of cancer‐related weight loss and sarcopenia in the UK and Ireland: incidence, prevalence, and clinical impact. JCSM Rapid Commun. 2020;3:91-102. DOI: https://doi.org/10.1002/rco2.19
Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47. DOI: https://doi.org/10.1200/JCO.2012.45.2722
Au PC, Li HL, Lee GK, Li GH, Chan M, Cheung BM, et al. Sarcopenia and mortality in cancer: a meta-analysis. Osteoporos Sarcopenia. 2021;7(Suppl 1):S28–33. DOI: https://doi.org/10.1016/j.afos.2021.03.002
Li HL, Au PC, Lee GK, Li GH, Chan M, Cheung BM, et al. Different definition of sarcopenia and mortality in cancer: a meta-analysis. Osteoporos Sarcopenia. 2021;7(Suppl 1):S34–8. DOI: https://doi.org/10.1016/j.afos.2021.02.005
Lee D, Kim NW, Kim JY, Lee JH, Noh JH, Lee H, et al. Sarcopenia’s prognostic impact on patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Clin Med. 2021;10(22):1–12. DOI: https://doi.org/10.3390/jcm10225329
Luo L, Shen X, Fang S, Wan T, Liu P, Li P, et al. Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis. BMC Cancer. 2023;23(1):127. DOI: https://doi.org/10.1186/s12885-023-10582-2
Surov A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, et al. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. Clin Nutr. 2021;40(10):5298–310. DOI: https://doi.org/10.1016/j.clnu.2021.08.023
Xia L, Zhao R, Wan Q, Wu Y, Zhou Y, Wang Y, et al. Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies. Cancer Med. 2020;9(21):7964–78. DOI: https://doi.org/10.1002/cam4.3428
Nipp RD, Fuchs G, El-Jawahri A, Mario J, Troschel FM, Greer JA, et al. Sarcopenia is associated with quality of life and depression in patients with advanced cancer. Oncologist. 2018;23(1):97–104. DOI: https://doi.org/10.1634/theoncologist.2017-0255
Wiegert EVM, de Oliveira LC, Calixto-Lima L, Borges NA, Rodrigues J, da Mota ESLMS, et al. Association between low muscle mass and survival in incurable cancer patients: a systematic review. Nutrition. 2020;72:110695. DOI: https://doi.org/10.1016/j.nut.2019.110695
Sugiyama K, Narita Y, Mitani S, Honda K, Masuishi T, Taniguchi H, et al. Baseline sarcopenia and skeletal muscle loss during chemotherapy affect survival outcomes in metastatic gastric cancer. Anticancer Res. 2018;38(10):5859–66. DOI: https://doi.org/10.21873/anticanres.12928
Li W, Zhu H, Dong H, Shi B, Qin Z, Huang F, et al. Body composition decrease and impact on clinical outcome in gastric cancer patients undergoing radical gastrectomy after neoadjuvant treatment. Nutr Cancer. 2024;77:1–12. DOI: https://doi.org/10.1080/01635581.2024.2418622
Amitani M, Oba T, Kiyosawa N, Morikawa H, Chino T, Soma A, et al. Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer. BMC Cancer. 2022;22(1):327. DOI: https://doi.org/10.1186/s12885-022-09443-1
Loosen SH, van den Bosch V, Gorgulho J, Schulze-Hagen M, Kandler J, Jordens MS, et al. Progressive sarcopenia correlates with poor response and outcome to immune checkpoint inhibitor therapy. J Clin Med. 2021;10(7):1–12. DOI: https://doi.org/10.3390/jcm10071361
Chaunzwa TL, Qian JM, Li Q, Ricciuti B, Nuernberg L, Johnson JW, et al. Body composition in advanced non-small cell lung cancer treated with immunotherapy. JAMA Oncol. 2024;10(6):773–83. DOI: https://doi.org/10.1001/jamaoncol.2024.1120
Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MAE, den Braver NR, Berkhof J, Langius JAE, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(12):1339–44. DOI: https://doi.org/10.1200/JCO.2015.63.6043
Cho KM, Park H, Oh DY, Lee KH, Han SW, Im SA, et al. Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. Oncotarget. 2017;8(45):79441–52. DOI: https://doi.org/10.18632/oncotarget.18345
Uemura S, Iwashita T, Ichikawa H, Iwasa Y, Mita N, Shiraki M, et al. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. Br J Nutr. 2020;125:1–8. DOI: https://doi.org/10.1017/S0007114520003463
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142. DOI: https://doi.org/10.1002/14651858.ED000142
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. DOI: https://doi.org/10.1016/j.jclinepi.2009.06.006
NHLBI N. Study Quality Assessment Tools. [cited 2025 Aug 1]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
Villaseca-Rojas Y, Varela-Melo J, Torres-Castro R, Vasconcello-Castillo L, Mazzucco G, Vilaró J, et al. Exercise capacity in children and adolescents with congenital heart disease: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:874700. DOI: https://doi.org/10.3389/fcvm.2022.874700
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. DOI: https://doi.org/10.1186/1471-2288-14-135
Cespedes Feliciano EM, Kroenke CH, Caan BJ. The obesity paradox in cancer: how important is muscle? Annu Rev Nutr. 2018;38:357–79. DOI: https://doi.org/10.1146/annurev-nutr-082117-051723
Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121–6. DOI: https://doi.org/10.4103/aam.aam_56_18
Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study. JAMA Oncol. 2017;3(12):e172319. DOI: https://doi.org/10.1001/jamaoncol.2017.2319
Jang MK, Park C, Hong S, Li H, Rhee E, Doorenbos AZ. Skeletal muscle mass change during chemotherapy: a systematic review and meta-analysis. Anticancer Res. 2020;40(5):2409–18. DOI: https://doi.org/10.21873/anticanres.14210
Fairman CM, Lønbro S, Cardaci T, VanderVeen BN, Nilsen TS, Murphy A. Muscle wasting in cancer: opportunities and challenges for exercise in clinical cancer trials. JCSM Rapid Commun. 2021;7:51–64. DOI: https://doi.org/10.1002/rco2.56
Ma S, Zhao G, Sui S, Chen X, Wu L, Wang T, et al. Tumor microenvironment and immune-related myositis: addressing muscle wasting in cancer immunotherapy. Front Immunol. 2025;16:1580108. DOI: https://doi.org/10.3389/fimmu.2025.1580108
Kakinuma K, Tsuruoka H, Morikawa K, Furuya N, Inoue T, Miyazawa T, et al. Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer. Thorac Cancer. 2018;9(1):99–104. DOI: https://doi.org/10.1111/1759-7714.12545
Williams GR, Chen Y, Kenzik KM, McDonald A, Shachar SS, Klepin HD, et al. Assessment of sarcopenia measures, survival, and disability in older adults before and after diagnosis with cancer. JAMA Netw Open. 2020;3(5):e204783. DOI: https://doi.org/10.1001/jamanetworkopen.2020.4783
Goncalves MD, Taylor S, Halpenny DF, Schwitzer E, Gandelman S, Jackson J, et al. Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer. Clin Radiol. 2018;73(5):505.e1–e8. DOI: https://doi.org/10.1016/j.crad.2017.12.004
Takai Y, Naito S, Kanno H, Yamagishi A, Yagi M, Sakurai T, et al. Body composition changes following chemotherapy for testicular germ cell tumor: obesity is the long-term problem. Asian J Andrology. 2021;03:458-62. DOI: https://doi.org/10.4103/aja202195
Park SE, Choi JH, Park JY, Kim BJ, Kim JG, Kim JW, et al. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer. Sci Rep. 2020;10(1):17683. DOI: https://doi.org/10.1038/s41598-020-74765-8
Lee MW, Jeon SK, Paik WH, Yoon JH, Joo I, Lee JM, et al. Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer. J Cachexia Sarcopenia Muscle. 2024;15(2):735–45. DOI: https://doi.org/10.1002/jcsm.13437
Lee H, Kim S, Chung M, Park J, Bang S, Park S, et al. Skeletal muscle mass predicts poor prognosis in patients with advanced pancreatic cancer undergoing second-line FOLFIRINOX chemotherapy. Nutr Cancer. 2019;71:1100–07. DOI: https://doi.org/10.1080/01635581.2019.1597906
Christensen JF, Simonsen C, Hojman P. Exercise training in cancer control and treatment. Compr Physiol. 2018;9(1):165–205. DOI: https://doi.org/10.1002/j.2040-4603.2019.tb00064.x
Pin F, Couch ME, Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr Opin Support Palliat Care. 2018;12(4):420–6. DOI: https://doi.org/10.1097/SPC.0000000000000382
Assenat E, Ben Abdelghani M, Gourgou S, Perrier H, Akouz FK, Desgrippes R, et al. Impact of lean body mass-based oxaliplatin dose calculation on neurotoxicity in adjuvant treatment of stage III colon cancer: results of the phase II randomized LEANOX trial. J Clin Oncol. 2025;43(23):2616–27. DOI: https://doi.org/10.1200/JCO-24-02754
Christensen JF, Jones LW, Andersen JL, Daugaard G, Rorth M, Hojman P. Muscle dysfunction in cancer patients. Ann Oncol. 2014;25(5):947–58. DOI: https://doi.org/10.1093/annonc/mdt551
Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260. DOI: https://doi.org/10.3389/fphys.2012.00260
Huo Z, Chong F, Luo S, Li N, Tong N, Lu Z, et al. Potential framework of the Global Leadership Initiative in Sarcopenia (GLIS) criteria based on muscle mass and/or strength for predicting survival in cancer patients: a nationwide multicenter cohort study. Clin Nutr. 2025;49:187–201. DOI: https://doi.org/10.1016/j.clnu.2025.04.021
Koeppel M, Mathis K, Schmitz KH, Wiskemann J. Muscle hypertrophy in cancer patients and survivors via strength training. A meta-analysis and meta-regression. Crit Rev Oncol Hematol. 2021;163:103371. DOI: https://doi.org/10.1016/j.critrevonc.2021.103371
Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 2020;11(2):366–80. DOI: https://doi.org/10.1002/jcsm.12525
Kirk B, Cawthon PM, Arai H, Ávila-Funes JA, Barazzoni R, Bhasin S, et al. The conceptual definition of sarcopenia: delphi consensus from the global leadership initiative in sarcopenia (GLIS). Age Ageing. 2024;53(3):1–10. DOI: https://doi.org/10.1093/ageing/afae052
Shimura M, Mizuma M, Motoi F, Kusaka A, Aoki S, Iseki M, et al. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer. Pancreatology. 2023;23(1):65–72. DOI: https://doi.org/10.1016/j.pan.2022.11.010
Jin K, Tang Y, Wang A, Hu Z, Liu C, Zhou H, et al. Body composition and response and outcome of neoadjuvant treatment for pancreatic cancer. Nutr Cancer. 2021;74:100–09. DOI: https://doi.org/10.1080/01635581.2020.1870704
Griffin OM, Duggan SN, Ryan R, McDermott R, Geoghegan J, Conlon KC. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer. Pancreatology. 2019;19(6):850–7. DOI: https://doi.org/10.1016/j.pan.2019.07.039
Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, Macdonald IA, et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2016;35(5):1103–9. DOI: https://doi.org/10.1016/j.clnu.2015.08.005
Aberle MR, Coolsen MME, Wenmaekers G, Volmer L, Brecheisen R, van Dijk D, et al. Skeletal muscle is independently associated with grade 3–4 toxicity in advanced stage pancreatic ductal adenocarcinoma patients receiving chemotherapy. Clin Nutr ESPEN. 2025;65:134–43. DOI: https://doi.org/10.1016/j.clnesp.2024.11.004
Davis MP, Bader N, Basting J, Vanenkevort E, Koppenhaver N, Patel A, et al. Are muscle and fat loss predictive of clinical events in pancreatic cancer? the importance of precision metrics. J Pain Symptom Manage. 2025;69(2):141–51. DOI: https://doi.org/10.1016/j.jpainsymman.2024.10.004
Miyake M, Owari T, Iwamoto T, Morizawa Y, Hori S, Marugami N, et al. Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapy. Support Care Cancer. 2018;26(4):1077–86. DOI: https://doi.org/10.1007/s00520-017-3924-0
MacDonald L, Rendon RA, Thana M, Wood L, MacFarlane R, Bell D, et al. An in-depth analysis on the effects of body composition in patients receiving neoadjuvant chemotherapy for urothelial cell carcinoma. Can Urol Assoc J. 2024;18(6):180–4. DOI: https://doi.org/10.5489/cuaj.8542
Rimar KJ, Glaser AP, Kundu S, Schaeffer EM, Meeks J, Psutka SP. Changes in lean muscle mass associated with neoadjuvant platinum-based chemotherapy in patients with muscle invasive bladder cancer. Bladder Cancer. 2018;4(4):411–8. DOI: https://doi.org/10.3233/BLC-180188
Lyon TD, Frank I, Takahashi N, Boorjian SA, Moynagh MR, Shah PH, et al. Sarcopenia and response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2019;17(3):216–22.e5. DOI: https://doi.org/10.1016/j.clgc.2019.03.007
Mitsui Y, Sadahira T, Araki M, Maruyama Y, Wada K, Tanimoto R, et al. Loss of psoas major muscle volume during systemic chemotherapy is related to worse prognosis in testicular cancer. Jpn J Clin Oncol. 2019;49(2):183–9. DOI: https://doi.org/10.1093/jjco/hyy166
Semerad O, Buchler T, Vejmelka J, Rozsypalova A, Tomesova J, Kohout P. Body composition changes during and after curative chemotherapy in patients with testicular cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Mar;166(1):91-96.10.5507/bp.2020.058. DOI: https://doi.org/10.5507/bp.2020.058
Buxton C, Schmeusser BN, Holt SK, Patil D, Phuong A, Chahine S, et al. A multicenter evaluation of treatment-associated changes in body composition in men with germ cell tumors of the testis: implications for adverse events and complications. Urology. 2024;192:74–82. DOI: https://doi.org/10.1016/j.urology.2024.06.030
Stene GB, Helbostad JL, Amundsen T, Sørhaug S, Hjelde H, Kaasa S, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 2015;54(3):340–8. DOI: https://doi.org/10.3109/0284186X.2014.953259
Kazemi-Bajestani S, Becher H, Butts C, Basappa N, Smylie N, Joy A, et al. Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung. J Cachexia. 2019;10:1070-82. DOI: https://doi.org/10.1002/jcsm.12451
Nattenmüller J, Wochner R, Muley T, Steins M, Hummler S, Teucher B, et al. Prognostic impact of CT-quantified muscle and fat distribution before and after first-line-chemotherapy in lung cancer patients. PLoS One. 2017;12(1):e0169136. DOI: https://doi.org/10.1371/journal.pone.0169136
Kidd AC, Cowell GW, Martin GA, Ferguson J, Fennell DA, Evison M, et al. The prevalence and prognostic significance of sarcopenia and adipopenia in pleural mesothelioma. Cancer Treat Res Commun. 2024;42:100856. DOI: https://doi.org/10.1016/j.ctarc.2024.100856
Khan A, Welman CJ, Abed A, O’Hanlon S, Redfern A, Azim S, et al. Association of computed tomography measures of muscle and adipose tissue and progressive changes throughout treatment with clinical endpoints in patients with advanced lung cancer treated with immune checkpoint inhibitors. Cancers (Basel). 2023;15(5):1–14. DOI: https://doi.org/10.3390/cancers15051382
Cortellini A, Palumbo P, Porzio G, Verna L, Giordano AV, Masciocchi C, et al. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Thorac Cancer. 2018;9(12):1623–30. DOI: https://doi.org/10.1111/1759-7714.12870
Sato R, Tokunaga M, Mizusawa J, Sato Y, Ito S, Takahari D, et al. Clinical impact of skeletal muscle mass change during the neoadjuvant chemotherapy period in patients with gastric cancer: an ancillary study of JCOG1002. World J Surg. 2024;48(1):163–74. DOI: https://doi.org/10.1002/wjs.12041
Juez LD, Priego P, Cuadrado M, Blázquez LA, Sánchez-Picot S, Gil P, et al. Impact of neoadjuvant treatment on body composition in patients with locally advanced gastric cancer. Cancers (Basel). 2024;16(13):1–11. DOI: https://doi.org/10.3390/cancers16132408
Mirkin KA, Luke FE, Gangi A, Pimiento JM, Jeong D, Hollenbeak CS, et al. Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: a multi-institutional analysis. J Gastrointest Oncol. 2017;8(3):589–95. DOI: https://doi.org/10.21037/jgo.2017.03.02
Matsuura N, Motoori M, Fujitani K, Nishizawa Y, Komatsu H, Miyazaki Y, et al. Correlation between skeletal muscle mass and adverse events of neoadjuvant chemotherapy in patients with gastric cancer. Oncology. 2020;98(1):29–34. DOI: https://doi.org/10.1159/000502613
Horii N, Kosaka T, Fujiwara R, Sato S, Akiyama H, Kunisaki C, et al. Psoas muscle depletion during preoperative chemotherapy for advanced gastric cancer has a negative impact on long-term outcomes after gastrectomy. Asia Pac J Clin Oncol. 2022;18:61–69 DOI: https://doi.org/10.1111/ajco.13514
Palmela C, Velho S, Agostinho L, Branco F, Santos M, Santos MPC, et al. Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer. J Gastric Cancer. 2017;17(1):74–87. DOI: https://doi.org/10.5230/jgc.2017.17.e8
den Boer RB, Jones KI, Ash S, van Boxel GI, Gillies RS, O’Donnell T, et al. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer. BJS Open. 2020;4(5):847–54. DOI: https://doi.org/10.1002/bjs5.50331
Rinninella E, Strippoli A, Cintoni M, Raoul P, Vivolo R, Di Salvatore M, et al. Body composition changes in gastric cancer patients during preoperative FLOT therapy: preliminary results of an Italian cohort study. Nutrients. 2021;13(3):1–13. DOI: https://doi.org/10.3390/nu13030960
Fujihata S, Ogawa R, Nakaya S, Hayakawa S, Okubo T, Sagawa H, et al. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer. Esophagus. 2021;18(2):258–66. DOI: https://doi.org/10.1007/s10388-020-00774-1
Dijksterhuis WPM, Pruijt MJ, van der Woude SO, Klaassen R, Kurk SA, van Oijen MGH, et al. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J Cachexia Sarcopenia Muscle. 2019;10(1):199–206. DOI: https://doi.org/10.1002/jcsm.12371
Hacker UT, Hasenclever D, Baber R, Linder N, Busse H, Obermannova R, et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol. 2022;33(7):685–92. DOI: https://doi.org/10.1016/j.annonc.2022.03.274
Awad S, Tan BH, Cui H, Bhalla A, Fearon KCH, Parsons SL, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr. 2012;31(1):74–7. DOI: https://doi.org/10.1016/j.clnu.2011.08.008
Onishi S, Tajika M, Tanaka T, Yamada K, Inaba Y, Abe T, et al. Prognostic impact of shift to low visceral fat mass after neoadjuvant chemotherapy in patients with esophageal cancer. Cancer Rep (Hoboken). 2024;7(8):e2084. DOI: https://doi.org/10.1002/cnr2.2084
Harada T, Tsuji T, Ueno J, Konishi N, Yanagisawa T, HIjikata H, et al. Clinical mechanism of muscle mass loss during neoadjuvant chemotherapy in older patients with esophageal cancer: a prospective cohort study. Dis Esophagus. 2025;38(1):1–13. DOI: https://doi.org/10.1093/dote/doae096
Yip C, Goh V, Davies A, Gossage J, Mitchell-Hay R, Hynes O, et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol. 2014;24(5):998–1005. DOI: https://doi.org/10.1007/s00330-014-3110-4
Miyata H, Sugimura K, Motoori M, Fujiwara Y, Omori T, Yanagimoto Y, et al. Clinical assessment of sarcopenia and changes in body composition during neoadjuvant chemotherapy for esophageal cancer. Anticancer Res. 2017;37(6):3053–9. DOI: https://doi.org/10.21873/anticanres.11660
Ishida T, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, et al. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy. Surgery. 2019;166(6):1041–7. DOI: https://doi.org/10.1016/j.surg.2019.07.033
Zhao Y, Xia M, Dang Y, Li Y, Zhao X, Kang N, et al. Impact of body composition on clinical outcomes in patients with esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy plus chemotherapy. Ann Ital Chir. 2024;95(3):284–93. DOI: https://doi.org/10.62713/aic.3336
Ying H, Chen Y, Hong Y, Ying K, Li S, Zhang Y, et al. L3-SMI as a predictor of overall survival in oesophageal cancer patients receiving PD-1 inhibitors combined with chemotherapy. Ann Med. 2025;57(1):2440114. DOI: https://doi.org/10.1080/07853890.2024.2440114
Wood N, Morton M, Shah SN, Yao M, Barnard H, Tewari S, et al. Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2023;169:55–63. DOI: https://doi.org/10.1016/j.ygyno.2022.11.024
Ubachs J, Koole SN, Lahaye M, Fabris C, Bruijs L, Schagen van Leeuwen J, et al. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study. Gynecol Oncol. 2020;159(3):706–11. DOI: https://doi.org/10.1016/j.ygyno.2020.09.042
Yoshino Y, Taguchi A, Nakajima Y, Takao M, Kashiyama T, Furusawa A, et al. Extreme skeletal muscle loss during induction chemotherapy is an independent predictor of poor survival in advanced epithelial ovarian cancer patients. J Obstet Gynaecol Res. 2020;91:2662-71. DOI: https://doi.org/10.1111/jog.14516
Del Grande M, Rizzo S, Nicolino GM, Colombo I, Rossi L, Manganaro L, et al. Computed tomography-based body composition in patients with ovarian cancer: association with chemotoxicity and prognosis. Fronti Oncol. 2021;11:1–9. DOI: https://doi.org/10.3389/fonc.2021.718815
van der Zanden V, van Soolingen NJ, Viddeleer AR, Trum JW, Amant F, Mourits MJE, et al. Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications. Eur J Surg Oncol. 2021;48:896-902. DOI: https://doi.org/10.1016/j.ejso.2021.10.015
Toama W, Wiederin J, Shanley R, Jewett P, Gu C, Shenoy C, et al. Impact of pectoralis muscle loss on cardiac outcome and survival in Cancer patients who received anthracycline based chemotherapy: retrospective study. BMC Cancer. 2022;22(1):763. DOI: https://doi.org/10.1186/s12885-022-09882-w
Roeland EJ, Phull H, Hagmann C, Sera C, Dullea AD, El-Jawahri A, et al. FIT: Functional and imaging testing for patients with metastatic cancer. Support Care Cancer. 2021 May;29(5):2771-75.10.1007/s00520-020-05730-4 DOI: https://doi.org/10.1007/s00520-020-05730-4
Oflazoglu U, Alacacioglu A, Varol U, Kucukzeybek Y, Salman T, Taskaynatan H, et al. Chemotherapy-induced sarcopenia in newly diagnosed cancer patients: Izmir Oncology Group (IZOG) study. Support Care Cancer. 2020;28(6):2899–910. DOI: https://doi.org/10.1007/s00520-019-05165-6
Daly LE, Power DG, O’Reilly A, Donnellan P, Cushen SJ, O’Sullivan K, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017;116(3):310–7. DOI: https://doi.org/10.1038/bjc.2016.431
Chen J, Huang X, Wei Q, Liu S, Song W, Liu M. The relationship between systemic therapies and low skeletal muscle mass in patients with intermediate and advanced hepatocellular carcinoma. Front Immunol. 2025;16:1557839. DOI: https://doi.org/10.3389/fimmu.2025.1557839
Shigefuku R, Iwasa M, Tanaka H, Tsukimoto M, Tamai Y, Fujiwara N, et al. Prognostic significance of psoas muscle index in unresectable hepatocellular carcinoma: comparative analysis of lenvatinib and atezolizumab plus bevacizumab. J Clin Med. 2024;13(19):1–12. DOI: https://doi.org/10.3390/jcm13195925
Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, et al. Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. Surgery (United States). 2019;165(2):329–36. DOI: https://doi.org/10.1016/j.surg.2018.07.031
Nozawa H, Emoto S, Murono K, Shuno Y, Kawai K, Sasaki K, et al. Change in skeletal muscle index and its prognostic significance in patients who underwent successful conversion therapy for initially unresectable colorectal cancer: observational study. The Adv Gastroenterol 2020;13:1–14. 10.1177 DOI: https://doi.org/10.1177/1756284820971197
Palle SS, Mollehave LT, Taheri-Kadkhoda Z, Johansen S, Larsen L, Hansen JW, et al. Multi-frequency bioelectrical impedance analysis (BIA) compared to magnetic resonance imaging (MRI) for estimation of fat-free mass in colorectal cancer patients treated with chemotherapy. Clin Nutr Espen. 2016;16:8–15. DOI: https://doi.org/10.1016/j.clnesp.2016.09.003
Huemer F, Schlintl V, Hecht S, Hackl H, Melchardt T, Rinnerthaler G, et al. Regorafenib is associated with increased skeletal muscle loss compared to TAS-102 in metastatic colorectal cancer. Clin Colorectal Cancer. 2019;18(2):159–66.e3. DOI: https://doi.org/10.1016/j.clcc.2019.04.003
Gallois C, Bourillon C, Auclin E, Artru P, Lièvre A, Lecomte T, et al. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):1–9. DOI: https://doi.org/10.1016/j.clinre.2020.101603
Jang MK, Park S, Park C, Doorenbos AZ, Go J, Kim S. Does neoadjuvant chemotherapy regimen affect sarcopenia status in patients with breast cancer? Breast. 2022;66:1–7. DOI: https://doi.org/10.1016/j.breast.2022.08.009
Campbell KL, Lane K, Martin AD, Gelmon KA, McKenzie DC. Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer. Cancer Nurs. 2007;30(2):95–100. DOI: https://doi.org/10.1097/01.NCC.0000265004.64440.5f
Jung GH, Kim JH, Chung MS. Changes in weight, body composition, and physical activity among patients with breast cancer under adjuvant chemotherapy. Eur J Oncol Nurs. 2020;44:101680. DOI: https://doi.org/10.1016/j.ejon.2019.101680
Camilleri GM, Delrieu L, Bouleuc C, Pierga JY, Cottu P, Berger F, et al. Prevalence and survival implications of malnutrition and sarcopenia in metastatic breast cancer: a longitudinal analysis. Clin Nutr. 2024;43(8):1710–8. DOI: https://doi.org/10.1016/j.clnu.2024.06.014
Zhang Y, Kang H, Zhao J, Wang Y, Cai W, Zhang X, et al. Neoadjuvant therapy increases the risk of metabolic disorders and osteosarcopenia in patients with early breast cancer. Jpn J Clin Oncol. 2024;54(9):959–66. DOI: https://doi.org/10.1093/jjco/hyae070
Rossi F, Lambertini M, Brunetti N, De Giorgis S, Razeti MG, Calabrese M, et al. Muscle mass loss in breast cancer patients of reproductive age (≤ 45 years) undergoing neoadjuvant chemotherapy. Radiol Med. 2023;128(1):49–57. DOI: https://doi.org/10.1007/s11547-022-01574-6
Karaca M, Alemdar MS, Deniz Karaca Ö, Kılar Y, Köker G, Sözel H, et al. Sarcopenia’s role in neoadjuvant chemotherapy outcomes for locally advanced breast cancer: a retrospective analysis. Med Sci Monit. 2024;30:e945240. DOI: https://doi.org/10.12659/MSM.945240
Lee BM, Cho Y, Kim JW, Ahn SG, Kim JH, Jeung HC, et al. Association between skeletal muscle loss and the response to neoadjuvant chemotherapy for breast cancer. Cancers. 2021;13(8):1–14. https://www.mdpi.com/2072-6694/13/8/1806 DOI: https://doi.org/10.3390/cancers13081806
Rossi F, Torri L, Lambertini M, De Giorgis S, Calabrese M, Tagliafico AS. Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area. Eur Radiol. 2020;30(8):4234–41. DOI: https://doi.org/10.1007/s00330-020-06799-5
Mazzuca F, Onesti CE, Roberto M, Di Girolamo M, Botticelli A, Begini P, et al. Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget. 2018;9(39):25714–22. DOI: https://doi.org/10.18632/oncotarget.25394
Xiao DY, Luo S, O’Brian K, Sanfilippo KM, Ganti A, Riedell P, et al. Longitudinal body composition changes in diffuse large b-cell lymphoma survivors: a retrospective cohort study of United States veterans. J Natl Cancer Inst. 2016;108(11):1–7. DOI: https://doi.org/10.1093/jnci/djw145
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Lukas Svendsen, Sandra Jensen, Stine Hansen, Victor Sørensen, Christoffer Johansen, Charlotte Suetta, Helle Pappot, Casper Simonsen, Lars Hermann Tang, Susanne Oksbjerg Dalton, Gunn Ammitzbøll, Bolette Skjødt Rafn
This work is licensed under a Creative Commons Attribution 4.0 International License.
